Sixty-four percent of patients continued receiving long-term iloprost therapy, 36% stopped iloprost, due to lower airway reactivity, clinical deterioration, or death.

• 64%25患者继续使用长期伊洛前列素吸入、36%25患者因为低气道反应性、临床恶化或死亡而停止使用伊洛前列素。